

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that CSPC Megalith Biopharmaceutical Co., Ltd. (“**CSPC Megalith**”), a subsidiary of the Company, has entered into an exclusive license agreement (the “**Agreement**”) with Radiance Biopharma, Inc. (“**Radiance Biopharma**”) for the development and commercialization of the Group’s SYS6005 (the “**Product**”), a recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate, in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada (the “**Territory**”).

Under the terms of the Agreement, CSPC Megalith agreed to grant an exclusive license to Radiance Biopharma to develop and commercialize the Product in the Territory. CSPC Megalith will receive upfront payments of US\$15 million and is also eligible to receive potential development and regulatory milestone payments of up to US\$150 million and potential sales milestone payments of up to US\$1,075 million, plus tiered royalties based on annual net sales of the Product in the Territory.

About SYS6005

Utilizing the Group’s proprietary enzyme-catalyzed site-specific antibody conjugation technology, the Product is able to direct the potent mitotic inhibitor MMAE specifically to ROR1 expressing cancer cells. The stability of the linker can also facilitate the delivery of high concentration of MMAE into the tumor and reduce side effects with the decrease in undesirable systemic exposure. Compared with normal tissues, ROR1 is highly expressed in a variety of hematological malignancies and solid tumors, and its expression is closely related to disease progression and treatment response. The aberrant expression of ROR1 and associated pro-proliferative signaling observed in many types of malignancies make ROR1 an attractive therapeutic target for anti-cancer drug development. The Product was

designed to have homogeneous DAR distribution, better stability of the proprietary linker and reduced drug to antibody ratio in order to improve blood stability and tumor-specific drug release for better safety profile and efficacy.

About Radiance Biopharma

Radiance Biopharma, based in Boston, Massachusetts, the United States, is focused on developing a pipeline of antibody-based cancer therapeutics including mono and bispecific Antibody Drug Conjugates (ADCs) for the treatment of cancer and to address other unmet medical needs. Marc Lippman, MD, a co-founder and Chairman of the Board of Radiance Biopharma, is a renowned oncologist and former founding board member of Seagen Inc., a leader in the field of ADCs, which was acquired by Pfizer Inc. in December 2023. For more information, please visit www.radiancebiopharma.com.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 19 February 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.